Lymphatic system

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

Retrieved on: 
Tuesday, January 10, 2023
Cell, Prostate cancer, Cancer, University, Lymphatic system, Multiple myeloma, Cyclophilin, Fatty liver disease, Hepatocellular carcinoma, Chronic liver disease, Protein, Ixazomib, Mouse, Carfilzomib, HEPA, Liver cancer, Artificial intelligence, Doctor of Philosophy, NASH, Pharmaceutical industry, Vaccine

The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical study which investigated the killing of cultured prostate cancer cells by rencofilstat in combination with a proteasome inhibitor, ixazomib.

Key Points: 
  • The presentation, entitled “A New Strategy to Increase Proteotoxic Stress in Prostate Cancer,” highlighted a preclinical study which investigated the killing of cultured prostate cancer cells by rencofilstat in combination with a proteasome inhibitor, ixazomib.
  • Proteosome inhibitors are a class of anti-cancer agents that are used for the treatment of multiple myeloma and other blood cancers.
  • The present study showed that rencofilstat could synergistically increase the proteotoxic stress and in vitro cancer killing properties of ixazomib.
  • In this preclinical study, rencofilstat and ixazomib were applied at low concentrations to several types of prostate cancer cell lines, and also to non-cancerous prostate cells.

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

Retrieved on: 
Tuesday, January 10, 2023
IND, Degenerative disease, T-cell lymphoma, Blood, Plasma, MDM2, Lymphatic system, Sanofi, Entrepreneurship, Mass spectrometry, Cancer, TPD, Therapy, AML, Acute myeloid leukemia, Leukemia, Safety, SAD, Biomarker, FDA, PD, HS, Inflammation, AD, Skin, Toxic leukoencephalopathy, Conference, IV, Patient, Apoptosis, Immunomodulatory imide drug, Cycle, Atopic dermatitis, MYD88, Research, STAT3, MAD, Hidradenitis suppurativa, Human, Investment, Doctor of Philosophy, DLBCL, Follicular lymphoma, Fine chemical, Pharmaceutical industry, Vaccine, IRAK4, Black Majesty, PBMC

WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023.

Key Points: 
  • WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023.
  • Initial Phase 2 clinical trials of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.
  • In December 2022 Kymera announced that Dose Level (DL) 1 had been completed with a total of 4 patients enrolled.
  • Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Company’s progress and 2023 goals.

Bionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Applications

Retrieved on: 
Tuesday, January 10, 2023
MDS, Q&A, Genome, Hospital, HRD, Lymphatic system, Lymphoma, AML, NGS, Chronic lymphocytic leukemia, Laboratory, CLL, OGM, Biomarker, Drug development, Genomics, Neural tube defect, Chromosome, Research, Cancer, SAN, Doctor of Philosophy, Breast cancer, Genetic variation, Vaccine, Pharmaceutical industry, Antibiotics, Symposium

It will feature four consecutive days of OGM presentations delivered by 25 different customers worldwide across a wide range of genetic diseases, cancer and cell bioprocessing applications.

Key Points: 
  • It will feature four consecutive days of OGM presentations delivered by 25 different customers worldwide across a wide range of genetic diseases, cancer and cell bioprocessing applications.
  • During these four days, customers will showcase their latest research findings using OGM in constitutional, hematologic malignancies, and solid tumor applications.
  • Each day will feature oral customer presentations, a live panel with Q&A and a wide range of scientific posters within the virtual exhibition hall.
  • Researchers will present their experiences using OGM to uncover genetic variation that contributes to rare undiagnosed genetic disease, developmental disorders and reproductive disorders.

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
IND, Luman Hamlin Weller, Non-Hodgkin lymphoma, Science, MHRA, Lymphoma, Therapy, Gilead Sciences, IKZF1, BTK, Biotechnology, Standby Equity Distribution Agreement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Safety, CLL, FDA, IKZF3, Immunotherapy, Head, ASH, Conference, Innovation, Lymphatic system, Food, Health care, Chronic lymphocytic leukemia, Society for Immunotherapy of Cancer, Patient, Cancer, SAN, Clinical trial, Sale, SITC, Annual general meeting, Pharmaceutical industry, Vaccine, Sanofi

SAN FRANCISCO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today outlined key objectives and anticipated milestones for 2023 and provided an overview of recent progress in a presentation at the 41st Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in H2 2023 based on emerging clinical data and feedback from the U.S. Food and Drug Administration (FDA).
  • In addition, Nurix expects to define a dose for Phase 1b cohort expansion in H2 2023.
  • New drug candidate: Nurix expects to select a new targeted protein degrader development candidate in 2023.
  • Research milestones: Nurix expects to achieve substantial research collaboration milestones throughout 2023 from its existing collaborations with Gilead Sciences and Sanofi.

Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones

Retrieved on: 
Monday, January 9, 2023
IND, NSCLC, Large-cell lung carcinoma, Menin, Cancer, CRC, Glycated hemoglobin, Lymphatic system, MM, Multiple myeloma, Colorectal cancer, Team, Death, Liraglutide, Safety, CLL, FDA, Pancreatic cancer, Mutation, PDAC, Maintenance, Acute leukemia, Conference, NPM1, ET, Chronic lymphocytic leukemia, Patient, MLL, Type 2, KRAS, Type 2 diabetes, Phase, FLT3, Diabetes, Pharmaceutical industry, Medical imaging, DLBCL, Osteopathic medicine in Canada

A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events .

Key Points: 
  • A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events .
  • “2022 was a year of strong execution and fundamental infrastructure build as we transitioned to a clinical-stage company and expanded our pipeline.
  • In addition, we anticipate initiating dosing imminently in our Phase I/Ib (COVALENT-102) study of BMF-219 in patients with KRAS-mutated solid tumors.
  • On track to announce a third development candidate from the FUSION platform in the first half of 2023.

Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics

Retrieved on: 
Monday, January 9, 2023
IND, Q&A, Sunitinib, Toxicology, GIST, APEX, Part, Pharmacokinetics, Mastocytosis, Conference, Therapy, SM, Patient, Lymphatic system, Cogent, HER2/neu, Pharmaceutical industry

“In 2023, we look forward to continuing the rapid development of bezuclastinib toward leadership positions in both Systemic Mastocytosis and GIST, while we enhance our impressive, growing portfolio of targeted cancer therapeutics.

Key Points: 
  • “In 2023, we look forward to continuing the rapid development of bezuclastinib toward leadership positions in both Systemic Mastocytosis and GIST, while we enhance our impressive, growing portfolio of targeted cancer therapeutics.
  • Phase 2 SUMMIT trial - present initial clinical data in patients with NonAdvSM in the second half of 2023.
  • Select FGFR2-mutant selective clinical candidate and initiate IND-enabling GLP toxicology studies in the first half of 2023.
  • Present initial preclinical data on two additional novel target programs with best-in-class potential out of the Cogent Research Team’s labs during 2023.

Clean Slate Ink Opens Second Location in Austin, TX Featuring the Asclepion PicoStar® and MeDioStar® Lasers backed by Astanza

Retrieved on: 
Monday, January 9, 2023
Slate, Silver, XL, Laser, Skin, Pulse, Hope, Human, Lymphatic system, Ink, Asclepeion, Taste, Hair removal, Orders of magnitude (area), Printed circuit board, Gold

AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clean Slate Ink , Round Rock’s leading laser provider, has expanded its laser tattoo and hair removal services to South Austin, featuring two new lasers, the Asclepion PicoStar® and MeDioStar®, backed by Astanza.

Key Points: 
  • AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clean Slate Ink , Round Rock’s leading laser provider, has expanded its laser tattoo and hair removal services to South Austin, featuring two new lasers, the Asclepion PicoStar® and MeDioStar®, backed by Astanza.
  • Since opening its doors in 2018, Clean Slate Ink quickly became a staple name in the greater Austin laser scene.
  • “Clean Slate Ink has grown tremendously over the years thanks to the amazing clients we’ve had the opportunity of serving and the cutting-edge technology we’ve invested in,” said Chris Harris, owner.
  • Customers can choose a Silver, Gold, Rose Gold, or Platinum Package with simple scheduling and no time limitations.

Syros Announces Clinical Updates and 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Disease, MDS, Phenotype, Toxicity, RARA, Roche, AML, Arsenic trioxide, Safety, Azacitidine, AUC, Pancreatic cancer, SELECT, Venetoclax, APL, BRAF, ASH, Partnership, Lymphatic system, Patient, Society, Syros, Pharmaceutical industry, Cmax

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.
  • Syros currently has over 75 clinical sites open for recruitment in 12 countries.
  • Syros expects to complete patient enrollment in SELECT-MDS-1 in the fourth quarter of 2023, with data to follow in the third quarter of 2024.
  • Syros is developing SY-2101, a novel oral form of arsenic trioxide (ATO) for the treatment of newly diagnosed APL patients.

Inflammation Levels Tied to Severity of Blood Cancer

Retrieved on: 
Wednesday, January 11, 2023
Cancer, Bone marrow, Death, Child, American Lebanese Syrian Associated Charities, Stanford University, AML, Doctor of Philosophy, NYU Langone Health, Lasri, Inflammation, Iscor, Radiation, University, Pathology, Physician, MDS, Gene, Ohio State University, Bacteria, Genetic code, Myelodysplastic syndrome, St. Jude Children's Research Hospital, Immunotherapy, Acute myeloid leukemia, Lymphatic system, Immune system, Patent, Hematopoietic stem cell transplantation, Dana–Farber Cancer Institute, Hermann, National Institutes of Health, Risk, Disease, Leukemia, Patient, Erasmus MC, Tumor microenvironment, Charitable organization, NYU, Aplastic anemia, Haematopoietic system, Pharmacotherapy, Vaccine, Dentistry, Pharmaceutical industry, Elias C. Aifantis

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Severe inflammation weakens the body's ability to kill cancerous blood cells in people with acute myeloid leukemia (AML), a new study shows.

Key Points: 
  • Leukemic patients with high iScores died at least four years earlier than those with low levels of inflammation.
  • Others may favor alternative therapies in cases of low inflammation tied to their cancer because their immune system does not necessarily need reinforcement.
  • Some 246 genes tied to inflammation were found to be highly or less active in adults with the disease, while 187 genes linked to inflammation similarly stood out among children.
  • The common blood cancer occurs mostly in adults, resulting annually in the deaths of more than 11,500 Americans.

Blood Cancer Foundation of Michigan Names Ann LeWalk Director of Development

Retrieved on: 
Tuesday, January 10, 2023
Education, Psychology, Lymphatic system, Coagulopathy, BA, BCFM, Patient, Walking, Management, Birth control, Medicine, Development

FARMINGTON HILLS, Mich., Jan. 10, 2023 /PRNewswire/ -- The Blood Cancer Foundation of Michigan has hired Ann Biscup LeWalk as its new Director of Development. The announcement was made by BCFM President and CEO Heidi Grix.

Key Points: 
  • Farmington Hills-based Blood Cancer Foundation of Michigan (BCFM), formerly Children's Leukemia Foundation of Michigan, has appointed Ann LeWalk as Director of Development
    FARMINGTON HILLS, Mich., Jan. 10, 2023 /PRNewswire/ -- The Blood Cancer Foundation of Michigan has hired Ann Biscup LeWalk as its new Director of Development.
  • LeWalk brings extensive non-profit experience to the organization, previously working with the bleeding disorders community for more than 20 years.
  • In her new role, she will serve as a key leadership team member and an active strategic partner in decisions affecting the children, adults and families served by The Blood Cancer Foundation of Michigan (BCFM).
  • "We are thrilled to have Ann join our team as we continue our 70+ year journey, supporting blood cancer patients and families in Michigan," Grix said.